EP3528848A4 - Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies - Google Patents

Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies Download PDF

Info

Publication number
EP3528848A4
EP3528848A4 EP17861307.1A EP17861307A EP3528848A4 EP 3528848 A4 EP3528848 A4 EP 3528848A4 EP 17861307 A EP17861307 A EP 17861307A EP 3528848 A4 EP3528848 A4 EP 3528848A4
Authority
EP
European Patent Office
Prior art keywords
dmpg
dmpc
egpg
lysopg
protective effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17861307.1A
Other languages
German (de)
French (fr)
Other versions
EP3528848A1 (en
Inventor
Lawrence Helson
George M. SHOPP
Annie Bouchard
Muhammed Majeed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/297,901 external-priority patent/US10449193B2/en
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of EP3528848A1 publication Critical patent/EP3528848A1/en
Publication of EP3528848A4 publication Critical patent/EP3528848A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
EP17861307.1A 2016-10-19 2017-10-19 Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies Withdrawn EP3528848A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/297,901 US10449193B2 (en) 2011-06-03 2016-10-19 Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
PCT/US2017/057446 WO2018075801A1 (en) 2016-10-19 2017-10-19 Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Publications (2)

Publication Number Publication Date
EP3528848A1 EP3528848A1 (en) 2019-08-28
EP3528848A4 true EP3528848A4 (en) 2020-07-15

Family

ID=62019674

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17861307.1A Withdrawn EP3528848A4 (en) 2016-10-19 2017-10-19 Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Country Status (8)

Country Link
EP (1) EP3528848A4 (en)
JP (1) JP2019531309A (en)
KR (1) KR20190042775A (en)
CN (2) CN109843331A (en)
AU (2) AU2017345473A1 (en)
CA (1) CA3039596C (en)
MX (1) MX2019004222A (en)
WO (1) WO2018075801A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP2021500318A (en) * 2017-10-19 2021-01-07 サインパス ファルマ, インク.Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC / DMPG, LYSOPG and LYSOPC against drugs that cause channel disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120308643A1 (en) * 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US20150343063A1 (en) * 2014-06-03 2015-12-03 Signpath Pharma Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20050233970A1 (en) * 2004-03-23 2005-10-20 Praecis Pharmaceuticals, Inc. Methods for treating long QT syndrome
WO2008093848A1 (en) * 2007-02-02 2008-08-07 Sunstar Inc. Composition for decreasing inflammation marker comprising phosphatidylcholine
JP5638204B2 (en) * 2009-05-29 2014-12-10 国立大学法人 岡山大学 Liposome preparation for oral administration and production method thereof
WO2012094033A1 (en) * 2011-01-05 2012-07-12 Livon Laboratories Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
EP2814497A4 (en) * 2012-02-16 2015-12-09 Vascular Biogenics Ltd Methods for treating psoriasis and vascular inflammation
AT515178A5 (en) * 2012-08-31 2015-07-15 Univ North Texas CURCUMIN-ER, A NANOCURCUMIN FROM LIPOSOMAL PLGA WITH CONTINUED RELEASE TO MINIMIZE QT EXTENSION TO CANCER THERAPY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120308643A1 (en) * 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US20150343063A1 (en) * 2014-06-03 2015-12-03 Signpath Pharma Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018075801A1 *

Also Published As

Publication number Publication date
EP3528848A1 (en) 2019-08-28
AU2020267307A1 (en) 2020-12-10
CA3039596A1 (en) 2018-04-26
CN109843331A (en) 2019-06-04
MX2019004222A (en) 2019-06-10
CA3039596C (en) 2022-04-12
AU2017345473A1 (en) 2019-04-18
CN111481508A (en) 2020-08-04
JP2019531309A (en) 2019-10-31
WO2018075801A1 (en) 2018-04-26
KR20190042775A (en) 2019-04-24

Similar Documents

Publication Publication Date Title
EP3151837A4 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
EP3538106A4 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies
EP3442706A4 (en) Sample collection and preservation devices, systems and methods
EP3210364B8 (en) Systems and methods for application security analysis
EP3463248A4 (en) Devices and methods for using medicament devices
EP3320347A4 (en) Systems, methods, and devices for self-digitization of samples
EP3197518A4 (en) Medicament preparation and treatment devices, methods, and systems
EP3420456B8 (en) Anti-replay systems and methods
EP3265217A4 (en) Tumbler systems and methods
EP3551835A4 (en) Wellhead systems and methods
EP3125970A4 (en) Medical access port, systems and methods of use thereof
EP3405634A4 (en) Door holding device and safety system
EP3400050A4 (en) Drug release device and use
EP3442567A4 (en) Anti-psma antibodies and use thereof
EP3510986A4 (en) Mobility device and mobility system
EP3150634A4 (en) Anti-muc1 antibody or antigen-binding fragment of same, and use thereof
EP3110352A4 (en) Spinal cage device, system, and methods of assembly and use
EP3209766A4 (en) Tissue sample processing system and associated methods
EP3100683A4 (en) Photoacoustic signal-processing device, photoacoustic signal-processing system, and photoacoustic signal-processing method
EP3435665A4 (en) Monitoring device and monitoring system
EP3488431A4 (en) Security monitoring system and methods
EP3509413A4 (en) Systems and methods for medicinal cannabis harvesting
EP3136948A4 (en) Systems and methods for non-intrusive drug impairment detection
EP3483873A4 (en) Noise reduction device and noise reduction system
EP3398968A4 (en) Pcsk9 antibody, antigen-binding fragment thereof, and medicinal application thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190402

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200615

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20200608BHEP

Ipc: A61K 47/24 20060101AFI20200608BHEP

Ipc: A61K 9/127 20060101ALI20200608BHEP

Ipc: A61K 31/506 20060101ALI20200608BHEP

Ipc: A61P 9/00 20060101ALI20200608BHEP

Ipc: A61K 31/683 20060101ALI20200608BHEP

Ipc: A61K 31/685 20060101ALI20200608BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220609

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221020